EMA Withdrawn: Clopidogrel/Acetylsalicylic acid Teva (clopidogrel;acetylsalicylic acid) — Teva Pharma B.V.

View source ↗

Summary

The EMA withdrew Teva's clopidogrel/acetylsalicylic acid combination product from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction

Drugs mentioned

• Clopidogrel/Acetylsalicylic acid Teva (clopidogrel; acetylsalicylic acid)

Snippet

Status: Withdrawn. Therapeutic area: Acute Coronary Syndrome;Myocardial Infarction. MAH: Teva Pharma B.V.. Decision date: 03/06/2016